Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
INFÓRMESE
¿Qué es EM?
Un trastorno neurológico crónico que afecta el sistema nervioso central, compuesto por el cerebro...
Más detalles
MATERIALES EDUCATIVOS
PREGUNTAS COMUNES
Lending Library
Symptoms
Treatment Options
Additional Resources
INVESTIGACIÓN
MS Awareness Month
DONAR
OBTENGA AYUDA
Programa de Salud y Bi...
Obtenga materiales educativos y referencias así como también la oportunidad de participar en...
Más información
Grants & Programs
Awareness Campaigns
GRUPOS DE APOYO
Events
Lending Library
Additional Resources
PARTICIPE
Mes de Concientización...
Una campaña anual a nivel nacional con objetivos para promover la comprensión de la EM y ayudar a...
Más información
Advocacy
COMPRAS A SOCIOS
VOLUNTARIO
Businesses
MS Research Trials
Outreach
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
QUIÉNES SOMOS
Programas y Subvenciones
Más detalles
Overview
Press Room
LIDERAZGO
Healthcare Advisory Board
ESTADOS FINANCIEROS
NUESTRA MISIÓN
Careers at MS Focus
Affiliations
PROGRAMA DE ENFRIAMIENTO
El programa de enfriamiento ofrece una variedad de artículos, sin cargo, para ayudar a las...
/Get-Help/MSF-Programs-Grants/Cooling-Program
Shop
Privacy
Terms of Use
Site Map
Early high-efficacy treatment reduces long-term disability in children with MS
septiembre 23, 2024
New research reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis patients.
Utilizing data from the French MS Registry, Italian MS Register, and the global MSBase Registry, researchers at the University of Melbourne, in Australia, analyzed the outcomes of 282 patients with pediatric-onset MS who began experiencing symptoms before the age of 18. Patients were divided into two groups based on when they initiated monoclonal antibody treatment: either between the ages of 12-17 or 20-22 years.
Using the Expanded Disability Status Scale to measure and monitor disability progression in MS, the study showed that patients who began treatment between the ages of 12-17 years had a mean absolute increase of only 0.4 points on the EDSS, compared to a 0.95-point increase in those who started treatment later.
Between the ages of 23 and 27, the increase in EDSS scores from baseline was 0.57 points lower in the early treatment group compared to the late treatment group. The benefits of early treatment persisted throughout the median follow-up period of 10.8 years. Researchers said the substantially lower risk of progressing to higher disability levels in the early treatment group was particularly evident in the moderate disability range, where further progression was reduced by up to 97 percent.
Because of limited evidence of the efficacy, safety, and effects of monoclonal antibodies on children's development, regulatory restrictions often delay access to these treatments for pediatric-onset MS patients until adulthood. The study’s authors argue their findings are a strong argument for rethinking current treatment guidelines. By allowing earlier access to effective treatments, the quality of life for children with MS can be significantly enhanced and the burden of long-term disability reduced.
The research team is dedicated to generating further evidence to support the treatment of pediatric-onset MS, with a particular focus on assessing the long-term risks of immunosuppressive therapies in this population.
The findings were presented at ECTRIMS 2024.
[Error loading the control 'FeaturedNews', check event log for more details]